Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IVVDNASDAQ:PMNNASDAQ:SAVANASDAQ:TELO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIVVDInvivyd$0.85-6.0%$0.63$0.35▼$2.74$101.45M0.44.49 million shs1.51 million shsPMNProMIS Neurosciences$0.48-10.1%$0.59$0.47▼$2.37$15.69M0.0276,565 shs47,899 shsSAVACassava Sciences$2.10-1.4%$1.67$1.15▼$42.20$101.45M-2.313.01 million shs992,870 shsTELOTelomir Pharmaceuticals$2.07-1.4%$2.77$1.98▼$8.40$61.61M0.17137,714 shs81,319 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIVVDInvivyd+20.15%+11.13%+38.38%-26.89%-53.40%PMNProMIS Neurosciences+5.76%+1.73%-9.23%-28.79%-69.39%SAVACassava Sciences+0.95%-4.91%+35.67%-7.39%-90.19%TELOTelomir Pharmaceuticals0.00%-8.30%-17.65%-49.03%-68.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIVVDInvivyd3.092 of 5 stars3.62.00.00.02.43.31.3PMNProMIS Neurosciences3.1512 of 5 stars3.55.00.00.03.80.80.6SAVACassava Sciences3.7441 of 5 stars3.31.00.04.73.30.01.3TELOTelomir Pharmaceuticals1.9397 of 5 stars3.81.00.00.01.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIVVDInvivyd 3.25Buy$5.85591.73% UpsidePMNProMIS Neurosciences 3.00Buy$4.50837.50% UpsideSAVACassava Sciences 2.50Moderate Buy$54.502,495.24% UpsideTELOTelomir Pharmaceuticals 3.50Strong Buy$15.00624.64% UpsideCurrent Analyst Ratings BreakdownLatest PMN, IVVD, SAVA, and TELO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $5.005/16/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.005/12/2025PMNProMIS NeurosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/1/2025PMNProMIS NeurosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/26/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/25/2025SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.003/20/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/5/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/4/2025SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIVVDInvivyd$36.69M2.77N/AN/A$1.61 per share0.53PMNProMIS NeurosciencesN/AN/AN/AN/A$0.20 per shareN/ASAVACassava SciencesN/AN/AN/AN/A$3.26 per shareN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIVVDInvivyd-$198.64M-$1.20N/A7.69N/AN/A-155.33%-114.88%8/13/2025 (Estimated)PMNProMIS Neurosciences-$13.21M-$0.05N/AN/AN/AN/A-636.20%-130.32%8/14/2025 (Estimated)SAVACassava Sciences-$97.22M-$1.50N/AN/AN/AN/A-88.05%-64.98%8/14/2025 (Estimated)TELOTelomir Pharmaceuticals-$16.53M-$0.42N/AN/AN/AN/A-1,170.58%-832.67%8/12/2025 (Estimated)Latest PMN, IVVD, SAVA, and TELO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IVVDInvivyd-$0.04-$0.14-$0.10-$0.14$34.45 million$11.30 million5/12/2025Q1 2025PMNProMIS Neurosciences-$0.14-$0.21-$0.07-$0.21N/AN/A5/12/2025Q1 2025TELOTelomir Pharmaceuticals-$0.10-$0.07+$0.03-$0.07N/AN/A5/8/2025Q1 2025SAVACassava SciencesN/A-$0.48N/A-$0.48N/AN/A3/31/2025Q4 2024PMNProMIS Neurosciences-$0.14-$0.02+$0.12-$0.02N/AN/A3/20/2025Q4 2024IVVDInvivyd-$0.25-$0.15+$0.10-$0.15$13.57 million$13.80 million3/3/2025Q4 2024SAVACassava Sciences-$0.68-$0.57+$0.11-$0.57N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIVVDInvivydN/AN/AN/AN/AN/APMNProMIS NeurosciencesN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIVVDInvivydN/A1.921.58PMNProMIS NeurosciencesN/A9.309.30SAVACassava SciencesN/A3.553.55TELOTelomir PharmaceuticalsN/A1.941.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIVVDInvivyd70.36%PMNProMIS Neurosciences50.13%SAVACassava Sciences38.05%TELOTelomir PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipIVVDInvivyd25.40%PMNProMIS Neurosciences6.11%SAVACassava Sciences2.40%TELOTelomir PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIVVDInvivyd100119.96 million98.21 millionOptionablePMNProMIS Neurosciences532.69 million31.25 millionNot OptionableSAVACassava Sciences3048.31 million43.78 millionOptionableTELOTelomir Pharmaceuticals129.76 millionN/AN/APMN, IVVD, SAVA, and TELO HeadlinesRecent News About These CompaniesTelomir Pharmaceuticals CFO Michelle Yanez Leaves Company; Resignation Was a Mutual SeparationMay 21, 2025 | marketwatch.comTelomir Pharmaceuticals Appoints New Chief Financial OfficerMay 21, 2025 | tipranks.comTelomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease INDMay 21, 2025 | accessnewswire.comTelomir PharmaceuticalsMay 19, 2025 | thepharmaletter.comTelomir unveils new drug candidate against resistant bacteriaMay 16, 2025 | investing.comTelomir Pharma touts breakthrough in drug-resistant infectionsMay 16, 2025 | thepharmaletter.comTELO Announces Exciting DiscoveryMay 15, 2025 | msn.comTelomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market OpportunityMay 15, 2025 | accessnewswire.comTELO Announces Promising Aging Reversal Test ResultsMay 8, 2025 | msn.comTelomir Pharmaceuticals Unveils Promising Preclinical Data on Telomir-1May 7, 2025 | tipranks.comTelomir Pharmaceuticals (TELO) Projected to Post Earnings on MondayMay 7, 2025 | marketbeat.comTelomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic DysphoniaMay 7, 2025 | accessnewswire.comWhy Telomir Pharmaceuticals, Inc.’s (TELO) Stock Is Up 6.57%May 3, 2025 | aaii.comGeode Capital Management LLC Has $1.71 Million Stock Holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)May 2, 2025 | marketbeat.comWhy Telomir Pharmaceuticals, Inc.’s (TELO) Stock Is Down 7.25%April 29, 2025 | aaii.comWhy Telomir Pharmaceuticals, Inc.’s (TELO) Stock Is Up 10.93%April 2, 2025 | aaii.comWhy Telomir Pharmaceuticals, Inc.’s (TELO) Stock Is Down 17.60%March 31, 2025 | aaii.comTelomir Pharmaceuticals, Inc. (TELO)March 21, 2025 | finance.yahoo.comTELO Study Shows Cancer-Related BreakthroughMarch 19, 2025 | msn.comTelomir Pharmaceuticals announces anti-cancer effects in prostate cancer animal modelMarch 19, 2025 | msn.comTelomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study ShowsMarch 19, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMN, IVVD, SAVA, and TELO Company DescriptionsInvivyd NASDAQ:IVVD$0.85 -0.05 (-5.96%) Closing price 04:00 PM EasternExtended Trading$0.84 -0.01 (-0.91%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.ProMIS Neurosciences NASDAQ:PMN$0.48 -0.05 (-10.13%) Closing price 04:00 PM EasternExtended Trading$0.50 +0.02 (+3.13%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Cassava Sciences NASDAQ:SAVA$2.10 -0.03 (-1.41%) Closing price 04:00 PM EasternExtended Trading$2.10 +0.00 (+0.24%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Telomir Pharmaceuticals NASDAQ:TELO$2.07 -0.03 (-1.43%) Closing price 04:00 PM EasternExtended Trading$2.06 0.00 (-0.24%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
